SCHEDULE: Rallybio Corp: Laurion Capital Discloses 5.72% Stake

Laurion Capital Management LP, along with individuals Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, has reported beneficial ownership of 5.72% of Rallybio Corp's common stock as of March 31, 2026.

Summary

• Laurion Capital Management LP, acting as an investment adviser to certain funds and accounts, along with individuals Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, have collectively disclosed beneficial ownership of 302,756 shares of Rallybio Corp's common stock.
• This holding represents 5.72% of the class of securities.
• The filing indicates that the Laurion Funds have the right to receive dividends and proceeds from the sale of these shares.
• Specifically, Laurion Capital Master Fund Ltd., one of the Laurion Funds, has the right to receive dividends or proceeds from the sale of more than 5% of the common stock.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new financial or strategic information about Rallybio Corp itself.

Positives

• Significant stake acquired by a notable investment manager, potentially indicating confidence in Rallybio Corp's future prospects.
• The filing is current as of March 31, 2026, providing up-to-date information on ownership.

Negatives

• The filing does not provide specific financial performance data or strategic updates for Rallybio Corp, focusing solely on ownership disclosure.

Risks

• Potential for increased market activity or volatility in Rallybio Corp's stock due to the significant stake held by Laurion Capital.
• The filing does not detail the investment strategy or intentions of Laurion Capital, leaving room for speculation regarding future actions.

Future Outlook

The filing does not contain forward-looking statements or guidance from Rallybio Corp. The future outlook is limited to the reporting persons' certification that the shares are held in the ordinary course of business.

Management Comments

• The reporting persons certify that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors. The disclosure by Laurion Capital Management LP of a 5.72% stake in Rallybio Corp suggests a significant but likely non-controlling interest, common among investment managers in the biotechnology sector.

Stakeholder Impact

• Shareholders: The disclosure may influence market perception of Rallybio Corp's investor base, potentially signaling institutional interest. However, without further information on Laurion Capital's intentions, the direct impact is uncertain.
• Management: The filing confirms a significant institutional holder, which may lead to increased engagement between management and Laurion Capital.
• Creditors: No direct impact is indicated.

Next Steps

• No specific next steps are outlined in the filing beyond the standard reporting requirements.

Key Dates

Keywords

Rallybio Corp, Schedule 13G, Laurion Capital Management LP, Beneficial Ownership, Common Stock, Investment Adviser, Securities Filing